Scientific Presentations & Publications

Drug development backed by sound research.

The publications and presentations highlighted below represent a sample of the team’s innovative research published by the Coherus Oncology team and our collaborators.

06/01/25

A randomized phase 2 study of casdozokitug, an IL-27 targeting antibody, in combination with toripalimab plus bevacizumab in patients with unresectable and/or locally advanced or metastatic hepatocellular carcinoma

Li, D., et al. 2025 ASCO Annual Meeting

04/28/25

Phase 1 study of anti-CCR8 antibody CHS-114 with and without anti-PD-1antibody toripalimab in patients with advanced solid tumors

Worden, F., et al. 2025 American Association for Cancer Research (AACR) Annual Meeting

01/24/25

Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, CHS-388) in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)

Li, D., et al. 2025 ASCO Gastrointestinal Cancers Symposium

11/09/24

CHS-114, an anti-CCR8 cytolytic monoclonal antibody that preferentially depletes intratumoral Tregs and induces antitumor immune responses

Ravindranathan, S., et al. 2024 SITC Annual Meeting

11/08/24

Casdozokitug, a first-in-class, anti-IL27 antagonistic antibody treatment promotes NK and T cell driven antitumor response in a Phase I study in patients with advanced solid tumors

Wang, X., et al. 2024 SITC Annual Meeting

10/21/24

Casdozokitug, a first-in-class, anti-IL27 antagonistic antibody treatment promotes NK and T cell driven activation and inflammatory response in a Phase I study of cancer patients with advanced solid tumors

Rajasekaran, N., et al. Cytokines 2024

09/10/24

CHS-114, an Anti-CCR8 Antibody That Selectively Depletes Intratumoral Tregs and Induces Antitumor Immune Responses

Wang, X. et al., CICON24, CRI-ENCI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE

09/08/24

Casdozokitug, a First-in-Class, Anti-IL-27 Antagonistic Antibody, Treatment Promotes NK and T cell Activation and Inflammatory Response in Phase I Study of Cancer Patients with Advanced Solid Tumors

Ravindranathan, S., et al. CICON24, CRI-ENCI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE

06/01/24

Preliminary results of a phase 1, first-in-human, dose escalation study of the anti-CCR8 cytolytic antibody, CHS-114 (formerly SRF114) in patients with advanced solid tumors

Patnaik, A., et al. 2024 ASCO Annual Meeting

04/08/24

Characterization of CHS-1000, an Fc-modified anti-ILT4 monoclonal antibody for reprogramming suppressive myeloid cells in solid tumors

Rajasekaran, N., et al. 2024 AACR Annual Meeting

12345

We have multiple novel immuno-oncology programs currently in our development pipeline.

See our Pipeline